Introduction
If, in 1983, Anthony Weetman had been the first to see strong positive fluorescence on thyrocytes from patients with Graves' and Hashimoto's diseases stained with a monoclonal antibody to HLA class II molecules [1] , what hypothesis would he have formulated? Simply, that the cells might become antigen-presenting cells (APCs) for their own autoantigens and initiate or perpetrate an autoimmune process, which is exactly what was postulated at the time [2] . However, the main question still remains: 'does this phenomenon actually occur in vivo?'. Let us anticipate one of the conclusions of our dissertation: although the hypothesis has not been definitely proven, neither has it been disproved.
Of course, compared with 10 or more years ago, we are all now much wiser about the molecular and cellular processes involved in effective antigen presentation. In particular, in 1983 little was known about endocytic vs. cytosolic antigen processing pathways, about the tertiary structure of HLA molecules and the nature of antigenic peptide association with them, about the influence of co-stimulatory signals on the induction of T cell activation vs. anergy, or about the differential activation requirements of naïve and memory T cells. Indeed, in taking account of the tremendous advances in understanding of these processes, we have acknowledged that expression of HLA class II by tissue parenchymal cells could have effects ranging from detrimental, by stimulating autoreactivity as originally proposed, through to beneficial, by helping to maintain peripheral self-tolerance
